VSTM – verastem, inc. (US:NASDAQ)

News

Verastem, Inc. (NASDAQ: VSTM) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Verastem, Inc. (NASDAQ: VSTM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.50 price target on the stock.
Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference
Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com